Calidi Biotherapeutics (CLDI) Competitors $1.36 -0.09 (-6.21%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends CLDI vs. ADAG, ASRT, ANIX, PWUP, ME, CTMX, ANL, KPTI, RVPH, and QNCXShould you be buying Calidi Biotherapeutics stock or one of its competitors? The main competitors of Calidi Biotherapeutics include Adagene (ADAG), Assertio (ASRT), Anixa Biosciences (ANIX), PowerUp Acquisition (PWUP), 23andMe (ME), CytomX Therapeutics (CTMX), Adlai Nortye (ANL), Karyopharm Therapeutics (KPTI), Reviva Pharmaceuticals (RVPH), and Quince Therapeutics (QNCX). These companies are all part of the "pharmaceutical products" industry. Calidi Biotherapeutics vs. Adagene Assertio Anixa Biosciences PowerUp Acquisition 23andMe CytomX Therapeutics Adlai Nortye Karyopharm Therapeutics Reviva Pharmaceuticals Quince Therapeutics Calidi Biotherapeutics (NYSE:CLDI) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, community ranking, risk, earnings, media sentiment, institutional ownership and dividends. Does the media favor CLDI or ADAG? In the previous week, Calidi Biotherapeutics had 2 more articles in the media than Adagene. MarketBeat recorded 2 mentions for Calidi Biotherapeutics and 0 mentions for Adagene. Calidi Biotherapeutics' average media sentiment score of 0.43 beat Adagene's score of 0.00 indicating that Calidi Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Calidi Biotherapeutics Neutral Adagene Neutral Which has more risk & volatility, CLDI or ADAG? Calidi Biotherapeutics has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Adagene has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Which has higher valuation and earnings, CLDI or ADAG? Adagene has higher revenue and earnings than Calidi Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalidi Biotherapeutics$50K355.72-$29.22MN/AN/AAdagene$815.75K111.25-$18.95MN/AN/A Do institutionals and insiders believe in CLDI or ADAG? 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 24.3% of Calidi Biotherapeutics shares are owned by company insiders. Comparatively, 21.2% of Adagene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer CLDI or ADAG? Adagene received 21 more outperform votes than Calidi Biotherapeutics when rated by MarketBeat users. CompanyUnderperformOutperformCalidi BiotherapeuticsN/AN/AAdageneOutperform Votes2180.77% Underperform Votes519.23% Do analysts prefer CLDI or ADAG? Calidi Biotherapeutics currently has a consensus target price of $16.67, suggesting a potential upside of 1,125.49%. Adagene has a consensus target price of $5.00, suggesting a potential upside of 143.90%. Given Calidi Biotherapeutics' higher possible upside, research analysts clearly believe Calidi Biotherapeutics is more favorable than Adagene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Adagene 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CLDI or ADAG more profitable? Company Net Margins Return on Equity Return on Assets Calidi BiotherapeuticsN/A N/A -344.45% Adagene N/A N/A N/A SummaryCalidi Biotherapeutics beats Adagene on 8 of the 12 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDI vs. The Competition Export to ExcelMetricCalidi BiotherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$18.96M$2.94B$5.14B$19.19BDividend YieldN/A1.90%5.09%3.62%P/E RatioN/A46.7390.0541.30Price / Sales355.72415.011,117.1417.58Price / CashN/A182.1043.0421.28Price / Book-0.593.894.785.32Net Income-$29.22M-$42.21M$120.31M$989.88M7 Day Performance-26.49%-2.15%-1.92%-3.54%1 Month Performance-36.74%4.20%11.51%-3.68%1 Year PerformanceN/A18.39%30.61%12.14% Calidi Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDICalidi Biotherapeutics2.341 of 5 stars$1.36-6.2%$16.67+1,125.5%N/A$18.96M$50,000.000.0041News CoverageGap DownHigh Trading VolumeADAGAdagene1.9972 of 5 stars$2.05-0.5%$5.00+143.9%+13.9%$90.76M$815,746.000.00260ASRTAssertio3.3686 of 5 stars$0.95+3.2%$3.25+242.2%-14.8%$90.69M$125.76M-1.2620Gap DownANIXAnixa Biosciences2.949 of 5 stars$2.80-1.8%$8.50+203.6%-28.8%$90.10M$210,000.00-7.315PWUPPowerUp AcquisitionN/A$11.43flatN/A+5.7%$88.81MN/A0.00N/AME23andMe2.3629 of 5 stars$3.40+1.5%$9.40+176.5%-81.5%$88.81M$219.64M-0.13770Positive NewsCTMXCytomX Therapeutics4.321 of 5 stars$1.12+0.9%$5.77+415.4%-18.7%$87.65M$101.21M6.53170News CoveragePositive NewsANLAdlai Nortye1.583 of 5 stars$2.36+3.1%$9.00+281.4%-75.7%$87.08M$5M0.00127Positive NewsGap UpKPTIKaryopharm Therapeutics3.8015 of 5 stars$0.68-3.3%$5.00+638.3%-16.2%$85.46M$148.44M-0.61380RVPHReviva Pharmaceuticals3.012 of 5 stars$2.53-3.1%$15.50+512.6%-63.5%$84.60MN/A-2.355High Trading VolumeQNCXQuince Therapeutics2.8954 of 5 stars$1.89-6.9%$8.50+349.7%+60.4%$83.16MN/A-1.6460Analyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Adagene Competitors Assertio Competitors Anixa Biosciences Competitors PowerUp Acquisition Competitors 23andMe Competitors CytomX Therapeutics Competitors Adlai Nortye Competitors Karyopharm Therapeutics Competitors Reviva Pharmaceuticals Competitors Quince Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CLDI) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
